NASDAQ: DMACDiamedica Therapeutics Inc Stock Ownership - Who owns Diamedica Therapeutics?
Insider buying vs selling
Have Diamedica Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David J. Wambeke | Chief Business Officer | 2023-04-10 | 468,750 | $1.60 | $750.00kBuy |
| Randall Michael Giuffre | Director | 2023-01-03 | 35,130 | $1.53 | $53.75kBuy |
| Amy L. Burroughs | Director | 2023-01-03 | 17,156 | $1.53 | $26.25kBuy |
| Richard D. Pilnik | Director | 2023-01-03 | 55,555 | $1.53 | $85.00kBuy |
| Charles Pauling Semba | Director | 2023-01-03 | 17,156 | $1.53 | $26.25kBuy |
| Randall Michael Giuffre | Director | 2022-12-09 | 37,079 | $1.43 | $53.02kBuy |
| Randall Michael Giuffre | Director | 2022-12-08 | 20,000 | $1.40 | $28.00kBuy |
| Randall Michael Giuffre | Director | 2022-12-07 | 22,574 | $1.40 | $31.60kBuy |
| Randall Michael Giuffre | Director | 2022-12-06 | 2,300 | $1.35 | $3.11kBuy |
| Richard D. Pilnik | Director | 2022-12-05 | 35,000 | $1.39 | $48.48kBuy |
DMAC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when DMAC insiders and whales buy or sell their stock.
DMAC Shareholders
What type of owners hold Diamedica Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Koch Thomas Von | 20.43% | 5,503,720 | $15.14M | Insider |
| Zhenyu Xiao | 3.74% | 1,007,100 | $2.77M | Insider |
| Vanguard Group Inc | 2.91% | 782,989 | $2.15M | Institution |
| David J. Wambeke | 1.74% | 468,750 | $1.29M | Insider |
| Randall Michael Giuffre | 1.57% | 421,757 | $1.16M | Insider |
| Jacob Asset Management Of New York LLC | 0.87% | 233,730 | $642.76k | Institution |
| Richard D. Pilnik | 0.78% | 209,882 | $577.18k | Insider |
| Geode Capital Management LLC | 0.69% | 184,870 | $508.39k | Institution |
| Northern Trust Corp | 0.34% | 90,825 | $249.77k | Institution |
| Amy L. Burroughs | 0.27% | 73,288 | $201.54k | Insider |
DMAC vs Biotech Stocks
Diamedica Therapeutics Stock Ownership FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.